FRAMINGHAM, Mass., September 20, 2017 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, today announced that the company will be making keynote and featured presentations at several scientific, business and drug development conferences in the Fall, focusing on biotechnology innovation and drug development for Alzheimer’s disease.

Highlights of the Alzheon presentations include:

  • Recent discovery of a novel therapeutic mechanism of action for lead clinical candidate ALZ-801, which inhibits formation of toxic beta amyloid oligomers, a key initiation factor in Alzheimer’s pathology;
  • Identification of optimal initial target population for efficient replication of efficacy results to support the first approval of ALZ-801 – a genetically-defined subpopulation of Alzheimer’s patients homozygous for APOE4 gene that can be diagnosed with a simple blood test;
  • Differentiated product profile of ALZ-801, a well-absorbed oral medication that readily penetrates the brain, with favorable safety profile and potential to stabilize Alzheimer’s disease progression.

“We look forward to sharing our scientific discoveries and pioneering Precision Medicine approach to Alzheimer’s disease with colleagues around the world.  We appreciate these invitations from leaders of the field to offer our insights on development of therapeutics for neurodegenerative disorders – a recognition that the Alzheon team has made an influential contribution to Alzheimer’s science and drug development,” said Martin Tolar, MD, PhD, Founder, President and CEO of Alzheon.  “Our recent findings also set the course to develop ALZ-801 as the first drug in a new class of medicines that intervenes in the formation of neurotoxic oligomers, and offers disease-modifying potential in Alzheimer’s as well as other currently untreatable neurological disorders.  Patients are waiting and we are diligently preparing for initiation of a confirmatory pivotal study of ALZ-801 in Alzheimer’s in the near future.”

Event:  EATRIS Translational Medicine 2017 Conference

  • Keynote Presentation: Novel Enveloping Mechanism of Action in Alzheimer’s Disease
  • Speaker: Petr Kocis, PhD, Vice President of Preclinical Development, Alzheon, Inc.
  • Session: Developing More Predictive Preclinical Tools to Better Reach Proof of Concept
  • Date: Tuesday, September 26 at 11:00 a.m., local time
  • Location: Prague, Czech Republic


Event:  European Neurotech Investor & Partnering Conference

  • Presentation: A Precision Medicine Approach to Alzheimer’s disease
  • Speaker: Martin Tolar, MD, PhD, Founder, President & CEO, Alzheon, Inc.
  • Session: Treatment for Alzheimer’s and Cognitive Disorders
  • Date: Tuesday, October 3 at 10:45 a.m., local time
  • Location: Geneva, Switzerland

Event:  World CDx Conference

  • Presentation: Precision Medicine for Alzheimer’s Disease: Applying Genomic Stratification of Patients Based on APOE4 for Clinical Efficacy
  • Speaker: Martin Tolar, MD, PhD, Founder, President & CEO, Alzheon, Inc.
  • Session: Successful Implementation of Biomarker Signatures: Clinical Trial Case Studies
  • Date: Wednesday, October 18 at 4:15 p.m., local time
  • Location: Boston, Mass.

Event:  Drug Development Innovation Programme Conference

  • Presentation: Controlling Protein Misfolding by Small Molecule in Alzheimer’s Disease
  • Speaker: Petr Kocis, PhD, Vice President of Preclinical Development, Alzheon
  • Date: Friday, November 3 at 11:30 a.m., local time
  • Location: Boston, Mass.
About Alzheon

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders.  Our lead Alzheimer’s clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of amyloid aggregation and neurotoxicity – hallmarks of Alzheimer’s disease.  ALZ-801 is a novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients.  Our clinical expertise and technology platform is focused on developing drug candidates using a Precision Medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients.


Kathryn Morris
The Yates Network